Advertisement

Topics

Effects of Mobility Dose in Surgical Intensive Care Unit Patients

2017-06-26 04:19:48 | BioPortfolio

Summary

The primary aim of this study is to assess if the mobility dose that patients receive in the surgical intensive care unit (SICU) predicts adverse discharge disposition (primary endpoint), and muscle wasting diagnosed by bedside ultrasound (secondary endpoint).

Description

Our research group aims to better understand how patients on the SICU are mobilized and the impact it has on adverse discharge disposition and functional outcome after hospital discharge.

We have previously developed and validated the Surgical Intensive Care Unit Optimal Mobilization Score (SOMS), an algorithm to guide and facilitate early mobilization to advance mobility of SICU patients (NCT01363102). In addition, we have established the use of bedside ultrasound technology to quantify cross sectional area of the rectus femoris muscle, which allows an objective, user-independent quantification of muscle wasting (NCT02270502).

In this study we measure the dose of mobility, defined as a function of both the mobility provided by nursing and physical therapists (e.g., sitting at the edge of the bed, ambulating) as well as its duration. We will build on an existing mobility intensity quantification tool (NCT01674608) and add a domain that quantifies its duration in order to obtain a broad picture of the mobilization of patients on the SICU. The mobility dose is expressed by the mobility quantification score that has been developed by our team. We will then test the hypotheses that mobilization dose in the ICU predicts discharge disposition, defined as discharge to facilities providing long-term care assistance for daily activities, including nursing homes and skilled nursing facilities, hospice at the patient's home, hospice in a health care facility; or in-hospital mortality. Further we will evaluate the association between mobility dose and cross sectional area of the rectus femoris muscle measured by bedside ultrasound as a potential reflection of ICU-acquired muscle weakness (exploratory outcome).

Mobilization Quantification score: MQS (Detailed table linked in reference section)

This score integrates the highest rated activities within each mobility session - from physical therapy and nursing. By multiplying the scale it gets greater and allows a better interpretation of mobility intensity. It adds value of mobility dose across sessions considering the entire spectrum of active participation of the patient over the day.

Some specifics:

- If patient achieves a level in between predefined MQS levels we score the closest lower level

- We collect mobility data for the night time by interviewing the day nurses and asking them about the patients' mobilization also during night time

- We round up the duration of each mobility session: Passive range of motion (PRM) conducted 4 times during the day counts as: 1*4=4 (corresponding to 4 units/hours)

- For each session, we calculate the highest mobility level for the duration of the mobility session: e.g. Patient is standing for 5 minutes before s/he walks with 2 assists for 10 minutes: 3*7=21 (adding up the duration of various activities within a session and multiplying it by the highest achieved mobility level). Sitting passively in the chair is an exception (see below).

Sitting:

- Sitting in the chair counts as a separate session. Per sitting session a maximum of 2 hours are counted. For example: if a patient was sitting for a duration of either 2, 4 or 5 hours, we would always count: 2*4=8

- For patients stepping/shuffling/walking to the chair we use level 5 every time the patient is doing it. E.g. patient is shuffling to the chair, sitting for 2 hours and then walking back: 5*1+2*4+5*1 =28

- Distinct sitting sessions are defined by the patient being back in bed in between the sessions of sitting in the chair. E.g. the patient gets actively to chair by stand-step/shuffle, sits in chair for 6 hours, during sitting session patient gets up twice and afterwards gets back to bed by stand-step/shuffle:

5*1(to chair)+2*4(sitting)+5*1(back to bed)+5*2(standing up 2x in between)=28

Study Design

Conditions

Sarcopenia

Location

Massachusetts General Hospital
Boston
Massachusetts
United States
02114

Status

Recruiting

Source

Massachusetts General Hospital

Results (where available)

View Results

Links

Published on BioPortfolio: 2017-06-26T04:19:48-0400

Clinical Trials [76 Associated Clinical Trials listed on BioPortfolio]

Clinical Trial to Assess the Preventive Effects of Cetylpyridinium Chloride on Sarcopenia

This study is to assess the impact on the prevention of sarcopenia after taking cetylpyridinium chloride targeting the patients of pre-sarcopenia or sarcopenia over the age of 60

Measurement of Sarcopenia at Post-stroke Rehabilitation Outcome

The purposes of this study are 1. To explore effect of sarcopenia on recovery of post stroke hemiplegia 2. To explore the effect of stroke on sarcopenia and relationship between the ...

Assessments of Sarcopenia Prevalence in Chronic Heart Failure Patients and in Subjects Before TAVI

The main objective was to assess the prevalence of sarcopenia in chronic heart failure patients and in patients before the trans aortic valvular implantation. The loss of muscle mass in c...

Prevalence of Sarcopenia and Its Geriatric Features

The goal of this study is to determine the prevalence of sarcopenia in a geriatric hospital ward. Sarcopenia is defined by a loss of muscle mass, loss of muscle strength and loss of muscl...

ERAS in Colorectal Surgery Diminishes the Negative Impact of Sarcopenia on Short Term Outcomes

So far, the impact of sarcopenia has been analysed only in patients undergoing traditional surgical procedures (laparotomy) or those with metastatic spread. As the ERAS protocol combined w...

PubMed Articles [126 Associated PubMed Articles listed on BioPortfolio]

Sarcopenia in patients with hip fracture: A multicenter cross-sectional study.

Sarcopenia is prevalent in older persons and is a risk factor for falls, fractures, and mortality. The aim of this study was to determine a) the feasibility of determining sarcopenia in patients with ...

Lack of knowledge and availability of diagnostic equipment could hinder the diagnosis of sarcopenia and its management.

Sarcopenia is an emerging clinical challenge in an ageing population and is associated with serious negative health outcomes. This study aimed to assess the current state of the art regarding the know...

Basis for Sarcopenia Screening With the SARC-CalF in Nursing Homes.

Sarcopenia is a major health problem of the older population. The European Working Group on Sarcopenia in Older People (EWGSOP) developed diagnostic criteria for diagnosis of sarcopenia that require a...

Sarcopenia and hospitalisation costs in older adults: a cross-sectional study.

The impact of sarcopenia on hospitalisation has been under intense investigation; however, little is known about the association between sarcopenia and their costs among hospitalised patients. The aim...

Vitamin B12 deficiency might be related to sarcopenia in older adults.

Sarcopenia and dynapenia are related to repeated falls, mobility restriction, depression, frailty, increased mortality and morbidity. The aim of this study is to evaluate the relationship between vita...

Medical and Biotech [MESH] Definitions

Progressive decline in muscle mass due to aging which results in decreased functional capacity of muscles.

More From BioPortfolio on "Effects of Mobility Dose in Surgical Intensive Care Unit Patients"

Quick Search
Advertisement
 

Searches Linking to this Trial